Previous trial evidence suggested potential risk of serious urinary tract infections (UTIs) and genital infections in type 2 diabetes patients using sodium glucose co-transporter-2 inhibitors (SGLT2) inhibitors. We conducted a systematic review and meta-analysis to assess the effects of SGLT2 inhibitors on UTIs and genital infections in patients with type 2 diabetes. In total, 77 RCTs involving 50,820 participants were eligible. The meta-analyses of randomized controlled trials ( Sodium glucose co-transporter-2 (SGLT2) inhibitors are one of the newest classes of glucose-lowering drugs for patients with type 2 diabetes mellitus (T2DM)
(CENTRAL), using both Medical Subject Heading (MeSH) and free text terms (Supplementary material: Search strategies). We also searched ClinicalTrials. gov to identify additional relevant trials, including serious adverse events and adverse events with frequency over 5% 20, 21 .
Eligibility criteria. We included randomized controlled trials (RCTs) of adult type 2 patients that compared SGLT2 inhibitor against placebo, lifestyle modification, or active antidiabetic drugs; had the study duration of at least 12 weeks; and explicitly reported outcome data regarding UTIs, genital infections, events suggestive of UTIs, or events suggestive of genital infections. The last two outcomes were defined as both non-specific signs, symptoms and abnormal laboratory findings suggestive of UTIs or genital infections as well as confirmed infections. We planned to include non-randomized studies (non-randomized controlled trials, cohort studies and case-control studies), using eligibility criteria for patients, interventions and control similar with the above. No studies, however, proved eligible.
Study selection. Paired reviewers, independently and in duplicate, screened the searched citations for initial eligibility and full texts for final eligibility, assessed risk of bias, and collected data from included studies, using standardized forms with detailed instructions. Disagreements were resolved through discussion between the two reviewers or arbitrated by a third reviewer.
Risk of bias assessment. We used the Cochrane Collaboration's tool 22 to assess the risk of bias of each RCT. When assessing the risk of bias for such items as random sequence generation, allocation concealment and blinding, we used the option of "probably yes" or "probably no" to replace "unclear" 23 . This approach has proved reliable and valid, and has been used before 24 .
Data extraction.
For each eligible RCT, we collected the following information.
• Study characteristics, including author name, year of publication, study design, sample size, length of follow-up, study phase, number of study sites, source of funding, and countries involved; • Patient characteristics, including age, gender, duration of diabetes, body mass index (BMI), HbA1c level, and fasting plasma glucose (FPG); • Intervention and control characteristics, including baseline treatment, and details of SGLT2 inhibitors and control group; • Outcomes, including the events of urinary tract infections (UTIs), suggestive of UTIs, genital infections and suggestive of genital infections as well as the patients included for analyses in each group.
For a trial, if the outcome data were not explicitly reported in the published study report, but available from the corresponding trial registry (ClinicalTrials.gov), we collected the outcome data from the trial registry. For an extension trial, if the initial treatment intervention was switched, we used the outcome data prior to that point. When a trial published multiple reports or follow up points, we collected all reports into a single study and used the data with longest follow up 25 .
Data analysis and rating quality of evidence. We separately analyzed UTIs, events suggestive of UTIs, genital infections, and events suggestive of genital infections. We used random-effects Mantel-Haenszel method to calculate relative risk (RR) and 95% confidence intervals (95% CIs) and explored statistical heterogeneity with 
. We also calculated the number needed for harm (NNH) for each outcome if the finding was significant.
According to the guidance for subgroup analyses 26 , we explored the following subgroup hypotheses to examine variability between studies: type of control (SGLT2 inhibitors vs. placebo, SGLT2 inhibitors vs. active treatment), length of follow up (26 weeks or shorter, 26-52 weeks, over 52 weeks), individual SGLT2 inhibitors (different SGLT2 inhibitors vs. control), and gender (male vs. female). For the analysis, we used the test for interaction by comparing the pooled estimates of across the defined subgroups. We also conducted random-effects multiple meta-regression analyses adjusting for type of control, length of follow up and individual SGLT2 inhibitors. The gender was not included for multiple regression analyses because only a limited number of trials reported this information.
We also conducted sensitivity analyses to examine the stability of our findings using alternative effect measures (odds ratio (OR) vs. RR), analysis models (fixed effect vs. random effects). We explored publication bias by applying funnel plot and Egger's test. Finally, we used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to assess the quality of evidence by outcomes 27 .
Results
The process of study selection was shown in Fig.1 . We initially identified 2,114 citations. After title and abstract screening, 174 were potentially eligible. Finally, 77 RCTs, published in 143 reports, met the inclusion criteria, and one trial 28 recruited patients with established cardiovascular disease. No non-randomized studies were eligible.
Study Characteristics. All 77 RCTs were sponsored by pharmaceutical companies. Among these trials, 58 (75.3%) were international studies, 51 (66.2%) were specifically labeled as phase III trials. Of these 77 RCTs, 77 (100%) adequately generated their randomization sequence; 75 (97.4%) adequately concealed allocation; 74 (96.1%) blinded patients and caregivers; the overall risk of bias was low. The details regarding risk of bias of each study was presented in Supplementary Table 1S .
The patient baseline characteristics of 77 trials were shown in Supplementary Table 2S . In total, those 77 trials enrolled 50,820 participants with sample size ranging from 44 to 7,028. The average duration of diabetes was 0.4 to 16.9 years across trials; the length of follow up ranged from 12 to 161 weeks (median 24 weeks); the mean age of patients ranged from 51.3 to 68. 5 Fig. 2 ). There was no evidence of publication bias for UTIs (Supplementary Figure 1S , Egger's test p = 0.45), and sensitivity analyses did not show important changes in pooled effects. The quality of evidence was moderate due to imprecision (Table 2) .
Subgroup analyses by type of individual SGLT2 inhibitors (interaction p = 0.03) showed a statistically significant difference in UTIs (Table 1 and Supplementary Figure 5S ), but other analyses by type of control (interaction p = 0.36), length of follow up (interaction p = 0.78), and gender (interaction p = 0.42) showed no statistical differences (Table 1 and Supplementary Figure 6S-8S) . The multiple meta-regression analysis showed similar findings (individual SGLT2 inhibitors: p = 0.01; type of control: p = 0.66; length of follow up: p = 0.44) ( Table 1 ). The analysis showed that dapagliflozin alone, with 18 trials involving 8,337 participants, increased the risk of UTIs (RR 1.34, 95% CI 1.11 to 1.63, I 2 = 0%), but not with other SGLT2 inhibitors (Table 1 and Supplementary Figure 5S) . Fig. 3 ). Sensitivity analyses did not show important changes in pooled effects. There was no evidence of publication bias for events suggestive of UTIs (Supplementary Figure 2S, Egger's test p = 0.78) . We rated the quality of evidence as high (Table 2) . Subgroup analyses by type of control (interaction p = 0.44), gender (interaction p = 0.29), length of Table 2 . GRADE evidence profile of SGLT2 inhibitors and urinary tract infections and genital infections in patients with type 2 diabetes. 1 The meta-analysis failed to meet optimal information size (OIS) criteria. 2 Baseline risk estimate for UTIs in a 5-year time frame comes from the control arm of included 68 studies with 1278 events in 14940 participants (86 per 1000) over amedian follow up of 24 weeks. 3 Baseline risk estimate for suggestive UTIs in a 5-year time frame comes from the control arm of included 17 studies with 146 events in 2532 participants (58 per 1000) over a median follow up of 48 weeks. 4 Funnel plot suggested some asymmetry (Supplementary Figure 3S) , and Egger's test showed publication bias (p = 0.01). 5 Baseline risk estimate for genital infections in a 5-year time frame comes from the control arm of included 56 studies with 216 events in 12552 participants (17 per 1000) over a median follow up of 24 weeks. 6 Funnel plot suggested some asymmetry (Supplementary Figure 4S) , and Egger's test showed publication bias (p = 0.001). Figure 9S-11S) ; meta-regression analyses also found no differences between effect estimates and the type of control (p = 0.50), length of follow up (p = 0.90) ( Table 1) .
Effects on genital infections. Fifty-six trials reported 1,737 genital infections events among 36,569 patients with SGLT2 inhibitors (raw event rate 4.7%). Pooling of those trials found an increased risk of genital infections for SGLT2 inhibitors (versus control: 1,521/24,017 vs. 216/12,552; RR 3.30, 95% CI 2.74 to 3.99, I 2 = 22%; RD 423 more, 95% CI 320 more to 550 more per 1000 over 5 years) ( Table 1 and Fig. 4) , with a NNH of 22. There was evidence of suspected publication bias for genital infections (Supplementary Figure 3S , Egger's test p = 0.01). Sensitivity analyses did not show important changes in pooled effects. We rated the quality of evidence as moderate due to publication bias ( (interaction p = 0.03) showed a statistically significant difference in genital infections (Table 1 and Supplementary  Figure 12S-14S) . Subgroup analyses by gender (interaction p = 0.74) showed no differential treatment effects (Table 1 and Supplementary Figure 15S) . The multiple meta-regression analysis consistently showed that effects differed by length of follow up (p = 0.02), and appeared to be non-statistically different among individual SGLT2 inhibitors (p = 0.09) ( Table 1 ). The analyses of individual drugs suggested increased risk of genital infections for canagliflozin (13 trials, RR 4.45, 95% CI 3.49 to 5.67), dapagliflozin (11 trials, RR 3.22, 95% CI 1.95 to 5.32), and empagliflozin (16 trials, RR 3.14, 95% CI 2.29 to 4.30) ( Table 1 and Supplementary Figure 14S) .
Effects on events suggestive of genital infections.
Information on events suggestive of genital infections was available in 15 trials, which reported 363 events exclusively in trials of dapagliflozin versus control (n = 6712, raw event rate 5.4%). Meta-analysis of these trials showed higher risk of events suggestive of genital infections for dapagliflozin compared with control (328/4,311 vs. 35/2,401; RR 3.92, 95% CI 2.66 to 5.78, I 2 = 14%: RD 237 more, 95% CI 134 more to 387 more per 1000 over 5 years) ( Table 1 and Fig. 5) , with a NNH of 17. There was evidence of suspected publication bias for events suggestive of genital infections (Supplementary Figure 4S , Egger's test p = 0.001). Sensitivity analyses did not show important changes in pooled effects. We rated the quality of evidence as moderate due to publication bias (Table 2) . Subgroup analyses by length of follow up (interaction p = 0.06), gender (interaction p = 0.10), type of control (interaction p = 0.83) showed no differential treatment effects (Table 1 and Supplementary Figure 16S-18S) . The meta-regression analyses also showed no association between the length of follow up (p = 0.07), type of control (p = 0.50) and effect estimates (Table 1) .
Discussion
Main findings. In this study, we found that SGLT2 inhibitors may increase the risk of genital infections. The subgroup analyses by length of follow up showed differential effects in genital infections, suggesting that the longer the use of SGLT2 inhibitors, the higher the risk of genital infections. The subgroup analysis by individual SGLT2 agents also showed that differential effects on genital infections. The above findings warrant a careful consideration of benefits and potential undesirable effects of these agents.
The current analysis has yet to establish the effect of SGLT2 inhibitors on the risk of UTIs. The finding of overall analysis was largely influenced by the inclusion of the EMPA-REG OUTCOME trial 28 , which accounted for 35% of the total weight in the analysis, and suggested no increase in UTIs with empagliflozin 31 . Removing the EMPA-REG OUTCOME trial, the pooled analysis suggested that SGLT2 inhibitors seemed to increase risk on UTIs (OR 1.10, 95% CI 1.01 to 1.19, I 2 = 0%). Given the ongoing large clinical trials, including CANVAS (Canagliflozin Cardiovascular Assessment Study) 32 , DECLARE -TIMI58 33 (Dapagliflozin Effect on CardiovascuLAR Events), NCT01986881 34 (Ertugliflozin), we anticipate that inclusion of such trials when available would offer important and confirmatory insights into this issue. In the subgroup analyses on UTIs, however, we found differential effects among SGLT2 inhibitors. The analysis on the events suggestive of UTIs also supported the findings.
Using the GRADE system, we assessed the quality of evidence. We found that there was no serious limitation in consistency and directness because the evidence came from research that directly compared SGLT2 inhibitors versus placebo or active hypoglycemia drugs in type 2 diabetes patients, and the tests showed low heterogeneity. On the basis of the collective information, the quality of evidence for trials reporting UTIs was moderate as a result of failure to meet optimal information size (OIS) criteria, and the quality for trials reporting genital infections and events suggestive genital was moderate due to suspected publication bias.
In summary, the current evidence confirmed that SGLT2 inhibitors increase the risk of genital infections, and also suggested that the effects on genital infections may differ among SGLT2 inhibitors. The effects of SGLT2 on UTIs remain uncertain, and the upcoming large trials may offer confirmatory results. Comparison with other studies. Four previous meta-analyses 3, 4, 35, 36 reported increased risk of both UTIs and genital infections associated with SGLT2 inhibitors. The first 35 Compared with the above studies, our study included a number of additional studies and three additional SGLT2 inhibitors (ertugliflozin, remogliflozin, sotagliflozin), including 77 trials of 50820 patients. Our results regarding genital infection were generally consistent with the previous findings. However, our analyses suggested that the impact of SGLT2 inhibitors were uncertain. This inference was made primarily due to the fact that the meta-analyses results are not robust to sensitivity analysis (by excluding the major trial), the quality of evidence is moderate, and that earlier systematic reviews produced inconsistent findings. Our confidence on the effect was lowered. In addition to the data on UTIs and genital infections, we also analyzed events suggestive of UTIs and events suggestive of genital infections data in contrast to earlier systematic reviews; our findings consolidated the undesirable effects of SGLT2 inhibitors on infections.
Strengths and Limitations. Our study has several strengths. First, in addition to journal reports, we included five unpublished trials from ClinicalTrials.gov, which provided additional outcome data. Second, we used rigorous approach to ensure the data were accurate. Particularly, we checked outcome data reported in ClincialTrials.gov versus journal reports for consistency. Third, we offered comprehensive analysis of outcomes, including UTIs, events suggestive of UTIs, genital infections and events suggestive of genital infections. The outcomes regarding events suggestive of UTIs and genital infections may provide support for our inferences. Fourth, we conducted subgroup analyses to explore the differences in risk of UTIs and genital infections and used the GRADE approach to assess quality of evidence.
Our study also has some limitations. Although the majority of trials used the same classification system for UTIs and genital infections (MedDRA), some other trials may have over-reported UTIs using simple symptoms alone. Second, for the outcomes of UTIs and genital infections, trials of dapagliflozin, canagliflozin and empagliflozin accounted the major body of evidence. The trials were, however, too few for the agents such as ertugliflozin, luseogliflozin, remogliflozin, sotagliflozin and tofogliflozin, and we thus combined those trials. The subgroup analysis examining differential effects among those agents was thus unable to disentangle the effects of those agents with very few trials. For the outcomes regarding events suggestive of UTIs and of genital infections, all the trials focused on dapagliflozin only.
Conclusion
In summary, the current RCT evidence showed that, SGLT2 inhibitors increase the risk of genital infections, and the effects may differ among SGLT2 inhibitors and trials with different follow up. The impact of SGLT2 inhibitors on the risk of UTIs remains uncertain; the upcoming major trials may provide important insights on this issue. When their results are available, an update meta-analysis is warranted.
